- Medicine Name: Enjaymo
- Generic Name: Sutimlimab-jome
- Dosage Form & Strength: Injection: 1,100 mg/22 mL (50 mg/mL) in a single-dose vial
- Manufactured By: Bioverativ USA Inc.
Enjaymo (sutimlimab-jome) is a classical complement inhibitor used for the treatment of hemolysis in adult patients with cold agglutinin disease (CAD).
Recommended Dosage: The recommended dosage of Enjaymo for patients with cold agglutinin disease is based on body weight. For patients weighing 39 kg to not more than 75 kg, the recommended dose is 6,500 mg and for those weighing 75 kg or beyond, the recommended dose is 7,500 mg. Administer doses of Enjaymo intravenously (IV) weekly for the first 2 weeks, with administration every 2 weeks thereafter. Administer it at the recommended dosage regimen time points, or within two days of these time points.
In case of a missed dose, administer as promptly as possible; thereafter, resume dosing every 2 weeks. If the duration after the final dose exceeds 17 days, administer this medication weekly for two weeks, with administration every two weeks thereafter.
All Trademarks and Brands that appear on the website belong to their respective owners and indianpharmanetwork does not lay any claim on them we only provide Information.